« Previous Next » The American Journal of Medicine
Volume 123, Issue 2 , Pages 151-157 , February 2010

Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk

Hedi Schelleman, PhD
- Center for Clinical Epidemiology and Biostatistics and Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia
- Requests for reprints should be addressed to Hedi Schelleman, PhD, University of Pennsylvania School of Medicine, 826 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021
Warren B. Bilker, PhD
- Center for Clinical Epidemiology and Biostatistics and Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia
Colleen M. Brensinger, MS
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
Fei Wan, MS
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
Yu-Xiao Yang, MD, MSCE
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia
- Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia
Sean Hennessy, PharmD, PhD
- Center for Clinical Epidemiology and Biostatistics and Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia

Association between initiation of each antihyperlipidemic agent (exposed versus unexposed) and hospitalization for gastrointestinal bleeding in chronic warfarin users. Each diamond represents the odds

Association between initiation of each antihyperlipidemic agent (exposed versus unexposed) and hospitalization for gastrointestinal bleeding in chronic warfarin users. Each diamond represents the odds ratio of interest, and the vertical line represents the 95% confidence interval. The data are presented on the log scale. All analyses are adjusted for age, sex, race, state, prior gastrointestinal bleed, diabetes, and number of prior warfarin prescriptions filled on the index date.
- Full-Size Image
- Download to PowerPoint

Funding: This project was funded by National Institute on Aging grant R01AG02152. Apart from suggestions from reviewers during the peer review process, the funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Part of the infrastructure for this study was funded by the Clinical and Translational Science Award 5KL2RR024132.

Conflict of Interest: Dr. Schelleman has had travel to scientific conferences paid for by pharmacoepidemiology training funds contributed by pharmaceutical manufacturers. Dr. Bilker has consulted for Johnson & Johnson and Astra Zeneca, unrelated to warfarin, fibrates, and statins. Ms. Brensinger has consulted for a law firm representing Pfizer, unrelated to warfarin, fibrates, and statins. Dr. Yang has served as a consultant for AstraZeneca and has received grant support from AstraZeneca, Wyeth-Ayerst Laboratories, and GlaxoSmithKline, unrelated to warfarin, fibrates, and statins. Dr. Hennessy has had funding from Pfizer and consulted for a law firm representing Bayer and Pfizer, unrelated to warfarin, fibrates, and statins. Mr. Wan had no potential conflict of interest to declare.

Authorship: All authors had access to the data and a role in writing the manuscript.

PII: S0002-9343(09)00862-6

doi: 10.1016/j.amjmed.2009.07.020

« Previous Next » The American Journal of Medicine
Volume 123, Issue 2 , Pages 151-157 , February 2010